WO1994016723A3 - Wound healing composition - Google Patents

Wound healing composition Download PDF

Info

Publication number
WO1994016723A3
WO1994016723A3 PCT/US1994/000799 US9400799W WO9416723A3 WO 1994016723 A3 WO1994016723 A3 WO 1994016723A3 US 9400799 W US9400799 W US 9400799W WO 9416723 A3 WO9416723 A3 WO 9416723A3
Authority
WO
WIPO (PCT)
Prior art keywords
wound healing
healing composition
growth factor
insulin
compositions
Prior art date
Application number
PCT/US1994/000799
Other languages
French (fr)
Other versions
WO1994016723A2 (en
Inventor
George N Cox
Thomas A Mustoe
Original Assignee
Synergen Inc
George N Cox
Thomas A Mustoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergen Inc, George N Cox, Thomas A Mustoe filed Critical Synergen Inc
Priority to EP94907292A priority Critical patent/EP0686040A1/en
Priority to KR1019950703140A priority patent/KR960700069A/en
Priority to AU60937/94A priority patent/AU6093794A/en
Priority to JP6517228A priority patent/JPH09500088A/en
Publication of WO1994016723A2 publication Critical patent/WO1994016723A2/en
Publication of WO1994016723A3 publication Critical patent/WO1994016723A3/en
Priority to NO952987A priority patent/NO952987L/en
Priority to FI953615A priority patent/FI953615A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical wound healing compositions are provided which comprise insulin-like growth factor-1 in combination with insulin-like growth factor binding protein. The pharmaceutical compositions are formulated for non-systemic administration. The present invention also provides methods of using such wound healing compositions.
PCT/US1994/000799 1993-01-29 1994-01-25 Wound healing composition WO1994016723A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP94907292A EP0686040A1 (en) 1993-01-29 1994-01-25 Wound healing composition
KR1019950703140A KR960700069A (en) 1993-01-29 1994-01-25 Wound Treatment Composition (WOUND HEALING COMPOSITION)
AU60937/94A AU6093794A (en) 1993-01-29 1994-01-25 Wound healing composition
JP6517228A JPH09500088A (en) 1993-01-29 1994-01-25 Wound healing composition
NO952987A NO952987L (en) 1993-01-29 1995-07-27 Wound healing mixture
FI953615A FI953615A (en) 1993-01-29 1995-07-28 Wound Healing Composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1103193A 1993-01-29 1993-01-29
US08/011,031 1993-01-29

Publications (2)

Publication Number Publication Date
WO1994016723A2 WO1994016723A2 (en) 1994-08-04
WO1994016723A3 true WO1994016723A3 (en) 1994-09-15

Family

ID=21748560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/000799 WO1994016723A2 (en) 1993-01-29 1994-01-25 Wound healing composition

Country Status (8)

Country Link
EP (1) EP0686040A1 (en)
JP (1) JPH09500088A (en)
KR (1) KR960700069A (en)
AU (1) AU6093794A (en)
CA (1) CA2154078A1 (en)
FI (1) FI953615A (en)
NO (1) NO952987L (en)
WO (1) WO1994016723A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
ATE274056T1 (en) * 1995-10-11 2004-09-15 Chiron Corp COMBINATION PDGF, KGF, IGF AND IGFBP FOR WOUND HEALING
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DK1141014T3 (en) 1999-01-06 2005-04-11 Genentech Inc Insulin-like growth factor (IGF) in mutant variant
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
ES2301547T3 (en) 2000-05-16 2008-07-01 Genentech, Inc. TREATMENT OF CARTILAGO DISORDERS.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000569A1 (en) * 1988-07-15 1990-01-25 Central Sydney Area Health Service Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
WO1992003471A1 (en) * 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
WO1992013556A1 (en) * 1991-02-12 1992-08-20 Genentech, Inc. Combination of igf-i and igfbp for anabolism
WO1994004030A1 (en) * 1992-08-26 1994-03-03 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000569A1 (en) * 1988-07-15 1990-01-25 Central Sydney Area Health Service Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
WO1992003471A1 (en) * 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
WO1992013556A1 (en) * 1991-02-12 1992-08-20 Genentech, Inc. Combination of igf-i and igfbp for anabolism
WO1994004030A1 (en) * 1992-08-26 1994-03-03 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury

Also Published As

Publication number Publication date
WO1994016723A2 (en) 1994-08-04
EP0686040A1 (en) 1995-12-13
NO952987L (en) 1995-08-30
KR960700069A (en) 1996-01-19
CA2154078A1 (en) 1994-08-04
NO952987D0 (en) 1995-07-27
FI953615A0 (en) 1995-07-28
JPH09500088A (en) 1997-01-07
AU6093794A (en) 1994-08-15
FI953615A (en) 1995-07-28

Similar Documents

Publication Publication Date Title
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
AU5018693A (en) Sustained-release protein formulations
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
AU4867697A (en) Oxadiazoles, processes for preparing them and their use as pharmaceutical compositions
CA2137203A1 (en) Protein kinase c inhibitors
MY117032A (en) A novel compound form.
CA2129820A1 (en) Dna sequences encoding novel growth/differentiation factors
AU2170592A (en) Protein compositions having reduced-hygroscopic properties and methods for preparing same
GB9113219D0 (en) Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
EP1251137A3 (en) Use of insulin-like growth factor agonist peptides
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
AU9127591A (en) Biologically active bactericidal/permeability-increasing protein fragments
CA2338684A1 (en) Injectable propofol formulations
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
AU1934495A (en) Formulations for il-11
WO2001005355A3 (en) Formulations for il-11
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
WO1998019697A3 (en) Novel pharmaceutical compositions
WO1994016723A3 (en) Wound healing composition
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU7352096A (en) Use of thioethers as antioxidant for peptides and proteins and compositions containing the thioethers
EP1080724A4 (en) Mtp activity-lowering compositions
EP0783521B8 (en) Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 261753

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2154078

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 953615

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994907292

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 501098

Country of ref document: US

Date of ref document: 19951017

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994907292

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994907292

Country of ref document: EP